59 related articles for article (PubMed ID: 38494922)
1. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
3. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract][Full Text] [Related]
4. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
Nair-Gupta P; Diem M; Reeves D; Wang W; Schulingkamp R; Sproesser K; Mattson B; Heidrich B; Mendonça M; Joseph J; Sendecki J; Foulk B; Chu G; Fink D; Jiao Q; Wu SJ; Packman K; Elsayed Y; Attar R; Gaudet F
Blood Adv; 2020 Mar; 4(5):906-919. PubMed ID: 32150609
[TBL] [Abstract][Full Text] [Related]
5. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Sallman DA; Kerre T; Havelange V; Poiré X; Lewalle P; Wang ES; Brayer JB; Davila ML; Moors I; Machiels JP; Awada A; Alcantar-Orozco EM; Borissova R; Braun N; Dheur MS; Gilham DE; Lonez C; Lehmann FF; Flament A
Lancet Haematol; 2023 Mar; 10(3):e191-e202. PubMed ID: 36764323
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
[TBL] [Abstract][Full Text] [Related]
8. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.
Pollyea DA; Altman JK; Assi R; Bixby D; Fathi AT; Foran JM; Gojo I; Hall AC; Jonas BA; Kishtagari A; Lancet J; Maness L; Mangan J; Mannis G; Marcucci G; Mims A; Moriarty K; Mustafa Ali M; Neff J; Nejati R; Olin R; Percival ME; Perl A; Przespolewski A; Rao D; Ravandi F; Shallis R; Shami PJ; Stein E; Stone RM; Sweet K; Thota S; Uy G; Vachhani P; Cassara CJ; Freedman-Cass DA; Stehman K
J Natl Compr Canc Netw; 2023 May; 21(5):503-513. PubMed ID: 37156478
[TBL] [Abstract][Full Text] [Related]
9. Modulating T Cell Responses by Targeting CD3.
Menon AP; Moreno B; Meraviglia-Crivelli D; Nonatelli F; Villanueva H; Barainka M; Zheleva A; van Santen HM; Pastor F
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831533
[TBL] [Abstract][Full Text] [Related]
10. Present and Future Role of Immune Targets in Acute Myeloid Leukemia.
Damiani D; Tiribelli M
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612249
[TBL] [Abstract][Full Text] [Related]
11. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
[TBL] [Abstract][Full Text] [Related]
12. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.
Boyiadzis M; Desai P; Daskalakis N; Donnellan W; Ferrante L; Goldberg JD; Grunwald MR; Guttke C; Li X; Perez-Simon JA; Salamero O; Tucker T; Xu X; Yang J; Pemmaraju N; Alonso-Dominguez JM
Clin Transl Sci; 2023 Mar; 16(3):429-435. PubMed ID: 36564917
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
Kubicka E; Lum LG; Huang M; Thakur A
Front Immunol; 2022; 13():899468. PubMed ID: 36389764
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.
Velegraki M; Stiff A; Papadaki HA; Li Z
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013147
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
